乙型肝炎肝硬化并发急性肾损伤患者临床特点及其危险因素分析*

doi:10.3969/j.issn.1672-5069.2021.04.018

摘要/Abstract

摘要： 目的分析总结乙型肝炎肝硬化患者并发急性肾损伤(AKI)的临床特点及其危险因素。方法 2015年4月～2020年2月我院收治的乙型肝炎肝硬化患者223例,采用ELISA法检测血清α羟丁酸脱氢酶(HBDH),使用分光光度计检测吲哚氰绿(ICG),采用简化的美国肾脏病膳食改善(MDRD)研究组发布的公式计算估算的肾小球滤过率(eGFR)。应用多因素Logistic回归分析影响乙型肝炎肝硬化并发AKI的独立危险因素。结果在本组223例乙型肝炎肝硬化患者中,并发AKI 41例(18.4%),选择82例未发生AKI 患者作对照,结果AKI组年龄≥50岁、合并糖尿病、高尿酸血症、腹水、感染和Child-Pugh C级比率分别为39.0%、26.8%、29.3%、80.5%、36.6%和53.7%,显著高于无AKI组(分别为20.7%、12.2%、13.4%、59.8%、17.1%和17.1%,P<0.05);血清HBDH和ICG水平分别为(184.2±21.3)U/L和(31.4±3.6)%,显著高于无AKI组【分别为(141.0±13.8)U/L和(15.6±1.9)%,P<0.05],而eGFR为(71.6±11.3)mL/min·(1.73 m²)^-1,显著低于无AKI组【(113.8±13.4)mL/min·(1.73 m²)^-1,P<0.05];Logistic回归分析显示年龄≥50岁[OR(95%CI)为3.0(1.1～8.6)]、合并糖尿病[OR(95%CI)为1.9(1.1～3.3)]、伴有高尿酸血症[OR(95%CI)为2.8(1.1～7.3)]、存在腹水[OR(95%CI)为2.6(1.0～6.6)]、伴有感染[OR(95%CI)为5.1(1.2～22.6)]、肝功能Child-Pugh C级[OR(95%CI)为3.6(1.5～8.9)]、血清HBDH水平高[OR(95%CI)为2.8(1.2～6.3)]和eGFR水平低[OR(95%CI)为2.4(1.3～4.4)]均为乙型肝炎肝硬化患者并发AKI的独立危险因素(P<0.05)。结论乙型肝炎肝硬化患者,特别是失代偿期患者,存在一些并发AKI的危险因素,如年龄大、伴有糖尿病、高尿酸血症、腹水、感染、肝功能分级为C级等。针对AKI发生的高危人群,临床应予以高度关注,及时诊治,才可能改善预后。

关键词: 肝硬化, 乙型肝炎, 急性肾损伤, α羟丁酸脱氢酶, 估算的肾小球滤过率, 危险因素

Abstract: Objective The aim of this study was to analyze the clinical features and risk factors of acute kidney injury (AKI) in patients with viral hepatitis B-induced liver cirrhosis (LC). Methods A total of 223 patients with hepatitis B cirrhosis were admitted to our hospital between April 2015 and February 2020, and the AKI incidence was found. Serum hydroxybutyrate-dehydrogenase (HBDH) and indocyanine green (ICG) were detected. The estimated glomerular filtration rate (eGFR) was calculated. The independent risk factors for occurrence AKI were analyzed by multivariate Logistic regression analysis. Results Out of the 223 patients with LC, 41 patients(18.4%) were found having AKI, and we selected 82 patients without AKI based on age and gender pair for control; the results showed that the percentages of aged≥50 yr, with diabetes, hyperuricemia, ascites, infection and Child-Pugh class C in patients with AKI were 39.0%,26.8%,29.3%,80.5%,36.6% and 53.7%, all significantly higher than (20.7%, 12.2%, 13.4%, 59.8%, 17.1% and 17.1%, respectively, P<0.05); serum HBDH and ICG levels in patients with AKI were (184.2±21.3)U/L and (31.4±3.6)%, both significantly higher than [(141.0±13.8)U/L and (15.6±1.9)%, respectively, P<0.05], while the eGFR was (71.6±11.3)mL/min·(1.73 m²)^-1, significantly lower than [(113.8±13.4)mL/min·(1.73 m²)^-1, P<0.05] in patients without AKI; the multivariate Logistic regression analysis demonstrated that aged ≥50 yr[OR(95%CI):3.0(1.1-8.6)], complicated by diabetes [OR(95%CI):1.9(1.1-3.3)], with hyperuricemia [OR(95%CI):2.8(1.1-7.3)], with ascites [OR(95%CI):2.6(1.0-6.6)], with infection [OR(95%CI):5.1(1.2-22.6)], Child-Pugh class C [OR(95%CI):3.6(1.5-8.9)], high serum HBDH level [OR(95%CI):2.8(1.2-6.3)] and lower eGFR [OR(95%CI):2.4(1.3-4.4)] were all the independent risk factors for occurrence of AKI in patients with LC induced by CHB(P<0.05). Conclusion AKI is more prone to patients with hepatitis B-induced liver cirrhosis, and some risk factors, such as eldly patients, with concomitant diabetes, hyperuricemia, ascites, infection, and poor liver functions, should be taken into consideration clinically, which means early diagnosis and appropriate management might improve the prognosis.

Key words: Liver cirrhosis, Hepatitis B, Acute kidney injury, Hydroxybutyrate-dehydrogenase, Estimated glomerular filtration rate, Risk factor

刘颖, 何显, 田志颖, 赵晓彦. 乙型肝炎肝硬化并发急性肾损伤患者临床特点及其危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 524-527.

Liu Ying, He Xian, Tian Zhiying, et al. Clinical features and risk factors of acute kidney injury in patients with viral hepatitis B-induced liver cirrhosis[J]. Journal of Practical Hepatology, 2021, 24(4): 524-527.

参考文献

[1] Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the international club of ascites (ICA) consensus document. J Hepatol, 2019, 71(4):811-822.
[2] Francoz C, Nadim MK, Durand FO. Kidney biomarkers in cirrhosis. J Hepatol, 2016, 65(4):809-824.
[3] Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol, 2018, 24(21):2300-2310.
[4] 中华医学会感染病学分会, 中华医学会肝病学分会, 北京大学第一医院感染疾病科肝病中心, 等. 慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志, 2020, 23(1):9-32.
[5] Fede G, D'Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol, 2012, 56(4):810-818.
[6] Theresa B, Elisabeth K. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep, 2017, 5(2):127-137.
[7] Pose E, Cardenas A. Translating our current understanding of ascites management into new therapies for patients with cirrhosis and fluid retention. Dig Dis, 2017, 35(4):402-410.
[8] Adebayo D, Neong SF, Wong F. Refractory ascites in liver cirrhosis. Am J Gastroenterol, 2019, 114(1):40-47.
[9] Parr SK, Siew ED. Delayed consequences of acute kidney injury. Adv Chron Kid Dis, 2016, 23(3):186-194.
[10] Umemura T, Joshita S, Shibata S, et al. Renal impairment is associated with increased risk of mortality in patients with cirrhosis: a retrospective cohort study. Medicine, 2019, 98(6):e14475.
[11] 曾龙驿, 江玮. 重视糖尿病肾病发生机制的研究. 中华医学杂志, 2016, 96(17):1313-1314.
[12] 王文娟, 宋琦, 丁惠国. 肝硬化患者急性肾损伤的临床特点及危险因素分析. 中华内科杂志, 2018, 57(12):912-916.
[13] Wong F, Jepsen P, Watson H, et al. Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver Int, 2018, 38(10):1785-1792.
[14] Wong F. The evolving concept of acute kidney injury in patients with cirrhosis. Nat Rev Gastroenterol Hepatol, 2015, 12(12):711-719.
[15] Levy GD, Rashid N, Niu F, et al. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol, 2014, 41(5): 955-962.
[16] Barreto R, Fagundes C, Guevara M, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology, 2014, 59(4):1505-1513.
[17] Devani K, Charilaou P, Jaiswal P, et al. Trends in hospitalization, acute kidney injury, and mortality in patients with spontaneous bacterial peritonitis. J Clin Gastroenterol, 2019, 53(2):e68-e74.
[18] 崔瑞冰, 阎明. 肝肾综合征的病理生理学及诊疗进展. 中华肝脏病杂志, 2017, 25(4):246-248.
[19] Møller S, Lee SS. Cirrhotic cardiomyopathy. J Hepatol, 2018, 69(4):958-960.
[20] 刘艺琪, 王芳芳, 李萍. 乙型肝炎肝硬化并发急性肾损伤的影响因素. 中华传染病杂志, 2018, 36(12):752-754.

乙型肝炎肝硬化并发急性肾损伤患者临床特点及其危险因素分析^*

Clinical features and risk factors of acute kidney injury in patients with viral hepatitis B-induced liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨艳秋, 程颢, 冯敏. 肝脏剪切波弹性成像对慢性乙型肝炎患者肝纤维化的评估价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 480-483.
[2]	吴慧, 宋波, 吕承秀, 田文君, 牛家峰. 慢性乙型肝炎患者血清内质网应激指标变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(4): 484-487.
[3]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.
[4]	鲁小龙, 解春宝. IL-6基因多态性对HBV相关ACLF患者短期预后的影响[J]. 实用肝脏病杂志, 2021, 24(4): 516-519.
[5]	金苏素, 颜华东. 血清肾上腺髓质素前体诊断失代偿期肝硬化并发细菌感染及其预测短期预后的价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 528-531.
[6]	江秋维, 黄理, 姚朝光. 乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者临床特征及其危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 532-535.
[7]	冯娟, 哈丽达·夏尔甫哈孜, 范晓棠, 任智慧, 才仁, 李亮, 何方平. 合并MAFLD的乙型肝炎肝硬化患者血清瘦素水平变化特点分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 536-539.
[8]	安西全, 李燕, 孟根才次克. 替诺福韦联合索拉非尼治疗乙型肝炎相关中晚期原发性肝癌患者临床观察[J]. 实用肝脏病杂志, 2021, 24(4): 600-602.
[9]	孙若楠, 张春清. 食管胃底静脉曲张破裂出血预防和治疗进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 607-610.
[10]	黄永群, 黄润强, 熊平安. 替诺福韦酯联合双重免疫方案阻断HBV携带孕妇母婴病毒传播效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 331-334.
[11]	徐文婷, 张继红, 韦冬珏, 李巍. 替诺福韦补救治疗rtM204位点突变的慢性乙型肝炎患者效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 335-338.
[12]	王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.
[13]	陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.
[14]	刘翔鸷, 刘振显, 王晓燕. 中老年非酒精性脂肪性肝病患者胆石症与代谢危险因素关系探讨[J]. 实用肝脏病杂志, 2021, 24(3): 363-366.
[15]	苏亚勇, 徐成润, 郭永木, 张惠勇, 刘双平, 陈小兰. 慢加急性乙型肝炎肝衰竭患者死亡危险因素和预后评分模型的构建[J]. 实用肝脏病杂志, 2021, 24(3): 391-394.